Creo Medical (GB:CREO) has released an update.
Creo Medical Group PLC, a medical device company specializing in surgical endoscopy, reports a 13% revenue increase to £30.8m for FY23, driven by a 2.5x rise in core product sales and positive feedback for its Speedboat UltraSlim device. Despite an operating loss of £24.8m, the loss was reduced from the previous year, and with a successful oversubscribed fundraise of £33.7m, the company is on track for its 2024 targets, buoyed by continued sales momentum and strong Q1-24 performance.
For further insights into GB:CREO stock, check out TipRanks’ Stock Analysis page.
